480 related articles for article (PubMed ID: 15151467)
1. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
2. Treprostinil for pulmonary hypertension.
Skoro-Sajer N; Lang I; Naeije R
Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901
[TBL] [Abstract][Full Text] [Related]
3. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
4. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
5. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
8. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
[TBL] [Abstract][Full Text] [Related]
9. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
10. Advances in prostanoid infusion therapy for pulmonary arterial hypertension.
Doran A; Harris S; Goetz B
J Infus Nurs; 2008; 31(6):336-45. PubMed ID: 19018187
[TBL] [Abstract][Full Text] [Related]
11. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ;
Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647
[TBL] [Abstract][Full Text] [Related]
13. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
14. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
15. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
[TBL] [Abstract][Full Text] [Related]
16. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
Saji T; Nakayama T; Ishikita T; Matsuura H
Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
[TBL] [Abstract][Full Text] [Related]
17. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.
Levy M; Celermajer DS; Bourges-Petit E; Del Cerro MJ; Bajolle F; Bonnet D
J Pediatr; 2011 Apr; 158(4):584-8. PubMed ID: 21035821
[TBL] [Abstract][Full Text] [Related]
18. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
McSwain CS; Benza R; Shapiro S; Hill N; Schilz R; Elliott CG; Zwicke DL; Oudiz RJ; Staszewski JP; Arneson CP; Wade M; Zaccardelli D; McLaughlin V
J Clin Pharmacol; 2008 Jan; 48(1):19-25. PubMed ID: 18094217
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
Sadushi-Koliçi R; Skoro-Sajer N; Zimmer D; Bonderman D; Schemper M; Klepetko W; Glatz J; Jakowitsch J; Lang IM
J Heart Lung Transplant; 2012 Jul; 31(7):735-43. PubMed ID: 22480725
[TBL] [Abstract][Full Text] [Related]
20. Advances in prostacyclin therapy for pulmonary arterial hypertension.
Eells PL
Crit Care Nurse; 2004 Apr; 24(2):42-8, 50-4. PubMed ID: 15098310
[No Abstract] [Full Text] [Related]
[Next] [New Search]